Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Underuse of antiplatelets and inappropriate use.

× No keyword cloud information.

7 in total

Review 1. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors: Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal: Circulation Date: 2002-07-16 Impact factor: 29.690

2. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale.

Authors:
Journal: Ann Intern Med Date: 2002-01-15 Impact factor: 25.391

3. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors:
Journal: Lancet Date: 1998-01-24 Impact factor: 79.321

4. Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?

Authors: Lara Monesi; Fausto Avanzini; Simona Barlera; Vittorio Caimi; Davide Lauri; Paolo Longoni; Daria Roccatagliata; Massimo Tombesi; Gianni Tognoni; Maria Carla Roncaglioni
Journal: Eur J Clin Pharmacol Date: 2005-07-15 Impact factor: 2.953

Review 5. Non-valvular atrial fibrillation and stroke prevention. National Blood Pressure Advisory Committee of the National Heart Foundation.

Authors: G J Hankey
Journal: Med J Aust Date: 2001-03-05 Impact factor: 7.738

6. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity.

Authors: S V Morant; A D McMahon; J G F Cleland; P G Davey; T M MacDonald
Journal: Br J Clin Pharmacol Date: 2004-02 Impact factor: 4.335

7. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors: L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal: Lancet Date: 1998-06-13 Impact factor: 79.321

7 in total